Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma

Jens Koopmann, Neal S. Fedarko, Alka Jain, Anirban Maitra, Christine Iacobuzio-Donahue, Ayman Rahman, Ralph H. Hruban, Charles J. Yeo, Michael Goggins

Research output: Contribution to journalArticlepeer-review

166 Scopus citations

Abstract

Objective: Pancreatic adenocarcinoma is a deadly disease with an overall 5-year patient survival of less than 5%. This dismal prognosis of pancreatic cancer is largely due to the advanced stage of the disease at presentation. If pancreatic cancer could be diagnosed more readily and accurately using serum markers, patient survival could theoretically be improved by enabling more patients to avail of surgical resection. One candidate tumor marker recently identified by global gene expression analysis of pancreatic cancer is the secreted glycophosphoprotein osteopontin (OPN). In this study, we evaluate OPN as a serum marker of pancreatic adenocarcinoma. Methods: In situ hybridization for OPN was performed on a pancreatic adenocarcinoma tissue microarray. Serum OPN levels were determined in preoperative sera from 50 patients with pancreatic cancer and 22 healthy control individuals by competitive ELISA. Results: In situ hybridization for OPN performed on a tissue microarray revealed strong OPN mRNA signal in tumor-infiltrating macrophages in 8 of 14 pancreatic adenocarcinomas. In contrast, OPN expression was not seen in the pancreatic cancer cells themselves, nor was it seen in normal pancreatic tissue or in the macrophages distant from the infiltrating cancer. Serum OPN levels, as measured by ELISA, were elevated in the sera of 50 patients with resectable pancreatic adenocarcinoma compared to 22 healthy control individuals (mean ± SD for OPN was 482 ± 170 ng/ml and 204 ± 65 ng/ml, respectively; P < 0.001). Using a cutoff level of 2 SD above the mean for healthy individuals, elevated OPN had sensitivity of 80% and specificity of 97% for pancreatic cancer. In contrast, only 62% of these patients with resectable pancreatic cancer had elevated CA19-9. Conclusion: Serum OPN may have utility as a diagnostic marker in patients with pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)487-491
Number of pages5
JournalCancer Epidemiology Biomarkers and Prevention
Volume13
Issue number3
StatePublished - Mar 2004

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Fingerprint

Dive into the research topics of 'Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma'. Together they form a unique fingerprint.

Cite this